ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [ 64 Cu]Cu-NOTA-Trodelvy
Molecular Pharmaceutics · 07.04.2025 · 22 (4) · 2266-2275
DOI: 10.1021/acs.molpharmaceut.5c00069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 10.03.2025. Verfasst von Wenpeng Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Antigens, Neoplasm, Copper Radioisotopes, Cell Adhesion Molecules. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Peking University First Hospital.
Abstract (Originalsprache)
Trop2 exhibits significantly elevated expression in numerous solid malignancies, playing a crucial role in tumor advancement, whereas its presence in healthy tissues is minimal. In this study, we investigated Trop2 expression in bladder cancer models using [64Cu]Cu-NOTA-Trodelvy for immunoPET imaging. In HT-1376 models, [64Cu]Cu-NOTA-Trodelvy effectively visualized tumor as early as 12 h p.i. (10.30 ± 1.45% ID/g), with tumor uptake increasing and peaking at 48 h p.i. (13.73 ± 1.16% ID/g), highlighting its potential for tumor imaging. Control groups also demonstrated low tumor uptake (5.27 ± 1.14% ID/g at 48 h in the blocking group; 6.33 ± 0.74% ID/g at 48 h in UM-UC-3; 4.50 ± 0.30% ID/g at 48 h in the [64Cu]Cu-NOTA-IgG group). Long-term fluorescence imaging further confirmed the tumor uptake rate in the IRDye 800CW-Trodelvy group was significantly higher than in the IRDye 800CW-Trodelvy blockade group (P < 0.001). Our findings demonstrated that [64Cu]Cu-NOTA-Trodelvy enables specific and prolonged tumor accumulation in bladder cancer models, providing precise and noninvasive monitoring of Trop2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China.
- Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, Wisconsin 53705, United States.
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China.
- Department of Urology, Peking University First Hospital, Beijing 100034, China.
- Institute of Urology, Peking University, Beijing 100034, China.
ORCID-Profile: Jonathan W Engle, Lei Kang, Weibo Cai
Förderung
- NCI NIH HHS
- National Cancer Institute
- Peking University First Hospital
- China Postdoctoral Science Foundation
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- National Natural Science Foundation of China
- Beijing Nova Program
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Huang, W., Wang, T., Chao, F., Yang, Q., Mixdorf, J. C., Li, L., Engle, J. W., Fan, Y., Kang, L., & Cai, W. (2025). ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [ 64 Cu]Cu-NOTA-Trodelvy. Molecular Pharmaceutics, 22(4), 2266-2275. https://doi.org/10.1021/acs.molpharmaceut.5c00069
Vancouver
Huang W, Wang T, Chao F, Yang Q, Mixdorf JC, Li L, et al. ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [ 64 Cu]Cu-NOTA-Trodelvy. Molecular Pharmaceutics. 2025;22(4):2266-2275. doi:10.1021/acs.molpharmaceut.5c00069
BibTeX
@article{Huang2025,
author = {Huang, Wenpeng and Wang, Tianyao and Chao, Fangfang and Yang, Qi and Mixdorf, Jason C and Li, Liming and Engle, Jonathan W and Fan, Yu and Kang, Lei and Cai, Weibo},
title = {ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [ 64 Cu]Cu-NOTA-Trodelvy},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {4},
pages = {2266--2275},
doi = {10.1021/acs.molpharmaceut.5c00069}
}
EUVIMED